Mucosal vaccination may be best route for fighting head, neck tumors
Therapeutic vaccines for mucosal cancers may work best when administered directly at the site of those tumors rather than elsewhere.
Therapeutic vaccines for mucosal cancers may work best when administered directly at the site of those tumors rather than elsewhere.
The traditional view is that recurrent tumors are resistant to therapy because they acquired additional genetic mutations that make them more aggressive and impervious to drugs. However, these research findings alter that view.
A therapeutic vaccine for women who are already harboring human papillomavirus (HPV) appeared to fight cervical cancer in a small, phase 1 study.
Daclizumab, which prevents organ rejection after renal transplant, improved survival in persons with breast cancer receiving a therapeutic vaccine.
A vaccine significantly increased survival in mice with breast cancer when given with the hormonal therapy letrozole, but not with tamoxifen.
Several newly approved drugs plus more in the pipeline present the real possibility of prolonging survival in men with advanced prostate cancer.
Many women with early breast cancer experienced a sustained immune response after immunization with a vaccine that fights HER2, and this may reduce their risk for more invasive cancer.
A vaccine for people newly diagnosed with glioblastoma multiforme—the most aggressive and highest-grade malignant glioma—is being tested at 20 sites nationwide in a phase II trial.
A quadrivalent human papillomavirus (HPV) vaccine to prevent anal cancer was shown to be safe and effective in a trial of healthy men who have sex with men.
Recent study results suggest that a targeted immunotherapy based on a poxvirus may make chemotherapy for advanced non-small cell lung cancer more effective and slow disease progression.